Caribou Biosciences Stock News

-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an expected

Garvin Jabusch at the Shelton Green Alpha Fund girds against global systemic risk.

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission

During the last session, Caribou Biosciences Inc. (NASDAQ:CRBU)’s traded shares were 0.36 million. At the end of the trading day, the stock’s price was $9.19, reflecting an intraday loss of -3.47% or -$0.33. The 52-week high for the CRBU share is $32.65, that puts it down -255.28 from that peak though still a striking 6.96% … Is Caribou Biosciences Inc. (NASDAQ: CRBU) Still A Buy After plugging 2.91% Last Week? Read More »

BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclini

BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinica

BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel H

BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Hau

The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.

In last trading session, Caribou Biosciences Inc. (NASDAQ:CRBU) saw 0.42 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $9.87 trading at $0.03 or 0.30% at ring of the bell on the day assigns it a market valuation of $607.20M. That closing price of CRBU’s stock is … Caribou Biosciences Inc. (NASDAQ:CRBU) Is Down -3.89% Over The Past 30 Days: Is There Trouble Ahead? Read More »

Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago quarter EPS of $0.05. The s

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40, compared to $0.09 from the yea

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Hau

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurw

Dr. Rizvi brings significant experience in oncology cell therapy development Dr. Rizvi brings significant experience in oncology cell therapy development